Medicine Overview of Pericon 1 1mcg Capsule
Oral
Prevention & Treatment of Secondary Hyperparathyroidism
Associated with Chronic Kidney Disease (Stage 3 & 4)
PTH <500 pg/mL: 1 mcg PO qDay OR 2 mcg PO 3 times/week
PTH >500 pg/mL: 2 mcg PO qDay OR 4 mcg PO 3 times/week
Do not administer 3 times/week dosing no more frequently than every other day
Titrate dose based on response.
Monitoring parameters (Stage 3 & 4)
Serum PTH at 2-4 week intervals
PTH same or increased: Increase by 1 mcg/day OR 2 mcg three times/week
PTH decreased <30%: Increase by 1 mcg/day OR 2 mcg three times/week
PTH decreased >30% or <60%: Maintain current dose
PTH decreased >60%: Decrease 1 mcg/day OR 2 mcg three times/week
PTH <60 pg/mL: Decrease 1 mcg/day OR 2 mcg three times/week
Monitor serum calcium and phosphorus frequently; reduce dose or stop the drug if calcium (in mg/dL) times phosphorus (in mg/dL) product >75
Patients receiving digitalis; digitalis toxicity is potentiated by hypercalcemia
Strong CYP3A4 inhibitors may increase paricalcitol AUC. May increase serum creatinine in pre-dialysis patients. Hepatic impairment
Lactation: not known if distributed into breast milk, use caution
>10%
Nausea (13%)
1-10%
Vomiting,Edema,Palpitation,Chills,Pneumonia,Lightheadedness,GI bleeding,Flu,Sepsis,Hypokalemia,Hypercalcemia,Increase in blood creatinine
Digitalis; ketoconazole & other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole. May interfere absorption w/ cholestyramine (cap only). Increased risk of hypercalcemia w/ prescription-based phosphate or vit D-related medicinal products & Ca-containing prep or thiazide diuretics. Mg- & Al-containing prep (eg, antacids, phosphate-binders).
Reviews
Clear filtersThere are no reviews yet.